Oncology Pharmacy: Are We Ready for Formulary and Medication Management?
A Test Case for Multiple Myeloma
Web Activity

• Release date: July 1, 2010
• Expiration date: January 1, 2012
• Estimated time to complete activity: 2.75 hours
• Compatible with (IE 6 and up, Firefox, Safari)

Target Audience

This activity has been designed to meet the educational needs of pharmacists, physicians, registered nurses, and other healthcare professionals.

Statement of Need/Program Overview

Oncology pharmacy management has evolved as cancer care becomes more complex and concerns about cost and patient access continue to emerge. Being able to assess the evidence-based data on therapies, deploying programs to assure safety, and evaluating the cost-effectiveness of therapeutic options are paramount to achieving the best possible outcomes in today's health care environment. Given a finite level of resources, it is vital that managed care professionals understand the relationship between costs and clinical outcomes for cancer treatments.

Using multiple myeloma as a test case example, this activity will recommend innovative approaches for managed care professionals to consider implementing within their current setting as well as extrapolating to other areas of oncology pharmacy management in the future. Participants in this activity will be awarded access to an Oncology Managed Care Pharmacy Tool Box containing examples of resources and tools that have been used successfully by clinicians, educators, peer review organizations, managed care organizations, and others to improve oncology care management.

Educational Objectives
After completing this activity, the participant should be better able to:

• Compare evidence-based data on treatment response rates and the corresponding impact on outcomes among multiple myeloma therapies
• Discuss how treatment guidelines for multiple myeloma can be integrated within a managed care setting with the goal to improve overall patient outcomes
• Explain the utility of pharmacoeconomic models that evaluate the cost effectiveness of therapeutic options for multiple myeloma
• Describe formulary and benefit design mechanisms, such as Value-Based Benefit Design, and their effect on therapeutic selection and outcomes for multiple myeloma
• Define specialty therapy management (STM) services that can be utilized for patients being treated for multiple myeloma

Distinguished Faculty

Carol Ann Huff, MD Assistant Professor of Oncology and Medicine Division of Hematologic Malignancies Director, Myeloma Program Sidney Kimmel Comprehensive Cancer Center Johns Hopkins University Click here for biography

Robert J. Lipsy, PharmD, BCPS, FASHP Clinical Assistant Professor Department of Pharmacy Practice and Sciences University of Arizona - College of Pharmacy Click here for biography

John J. Mahoney, MD, MPH Medical Director Florida Health Care Coalition Consulting Medical Director JC Consulting Group, Inc. Click here for biography

Daniel C. Malone, PhD, RPh Professor, Departments of Pharmacy Practice and Science/Public Health University of Arizona - College of Pharmacy Click here for biography

Activity Agenda

Response Rates, Progression-Free Survival, Quality of Life:
Defining the Managed Care Outcomes for Multiple Myeloma Treatments
Carol Ann Huff, MD

Pharmacoeconomic Analyses and High Cost Therapies:
Making Informed Decisions on Resource Allocations for Multiple Myeloma
Daniel C. Malone, PhD, RPh

Current and Emerging Benefit Designs: Applications for Oncology Therapies
John J. Mahoney, MD, MPH

Implementing Oncology Formulary and Medication Management Strategies:
A Test Case for Multiple Myeloma
Robert J. Lipsy, PharmD, BCPS, FASHP

Physician Accreditation Statement

This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint sponsorship of Postgraduate Institute for Medicine (PIM) and Impact Education, LLC. PIM is accredited by the ACCME to provide continuing medical education for physicians.

Credit Designation
Postgraduate Institute for Medicine designates this educational activity for a maximum of 2.75 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Pharmacist Accreditation Statement

	Postgraduate Institute for Medicine is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.

Credit Designation
Postgraduate Institute for Medicine designates this continuing education activity for 2.9 contact hours (.29 CEUs) of the Accreditation Council for Pharmacy Education.

• (Universal Activity Number – 0809-9999-10-109-H01-P)

Nursing Credit Designation

This educational activity for 2.9 contact hours is provided by Postgraduate Institute for Medicine.

Accreditation Statement

Postgraduate Institute for Medicine is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center's Commission on Accreditation.

Fee Information

There is no fee for this educational activity.

Type of Activity

Knowledge-based

Disclosure of Conflicts of Interest

Postgraduate Institute for Medicine (PIM) assesses conflict of interest with its instructors, planners, managers, and other individuals who are in a position to control the content of CME activities. All relevant conflicts of interest that are identified are thoroughly vetted by PIM for fair balance, scientific objectivity of studies utilized in this activity, and patient care recommendations. PIM is committed to providing its learners with high quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest or a commercial interest.

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

The planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

Method of Participation

There are no fees for participating and receiving CME/CE credit for this activity. During the period July 1, 2010 through January 1, 2012, participants must 1) read the learning objectives and faculty disclosures; 2) study the educational activity; 3) complete the online posttest by recording the best answer to each question; and 4) complete the online evaluation form. Upon successful completion of the posttest (70% or better), you will have immediate access to an online certificate to download and print for your records.

Media

Internet

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Postgraduate Institute for Medicine (PIM), Impact Education, LLC, and Celgene Corporation do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of PIM, Impact Education, LLC, or Celgene Corporation. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications on dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.